Send to

Choose Destination
Expert Rev Anticancer Ther. 2016 Oct;16(10):1011-8. doi: 10.1080/14737140.2016.1230020. Epub 2016 Sep 22.

The safety and efficacy of sonidegib for the treatment of locally advanced basal cell carcinoma.

Author information

a Dermatology Centre, Salford Royal NHS Foundation Trust , University of Manchester, Manchester Academic Health Science Centre , Manchester , UK.
b St John's Institute of Dermatology , St Thomas' Hospital , London , UK.



Basal cell carcinomas (BCCs) are the commonest malignancy in the Western world. Locally advanced BCCs (laBCCs) represent tumours that have developed in difficult-to-treat facial sites, aggressively recurrent tumours, large neglected tumours and those in which current treatment options are excluded by clinical or patient-driven criteria. It is estimated laBCCs represent 1% of BCCs.


Sonidegib is an oral hedgehog pathway inhibitor with a novel structure. It has recently been licensed for the treatment of laBCC. This article provides a comprehensive review of the literature regarding sonidegib, detailing the pharmacology of the compound, clinical trial data, competitor compounds and a future perspective. Expert commentary: Sonidegib is a novel smoothened (SMO) inhibitor with comparable efficacy to vismodegib, with patient response rates of 44% (sonidegib) and 43% (vismodegib). The adverse effect profile of these two treatments is similar with the main effects being considered to be class effects of SMO inhibitors.


Basal cell carcinoma; hedgehog pathway inhibitors; locally advanced basal cell carcinoma; small-molecule inhibitors; smoothened inhibitors; sonidegib

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center